- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Accupro - antihypertensive drug, ACE inhibitor.
Arterial hypertension, chronic heart failure.
1 coated tablet contains 40 mg quinapril hydrochloride.
Excipients: magnesium carbonate, magnesium stearate, lactose, gelatin, crospovidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, titanium dioxide, macrogol 400, candelae wax, Opadry White OY-S-7331.
No customer reviews for the moment.
Dosage and Administration
Goldline Plus is taken in one capsule per day in the first half of the day. Treatment begins with a lower dosage of 10 mg. If within 4 weeks of admission is not achieved weight loss of more than 2 kg, move to a large dosage - 15 mg. The effect of the drug develops gradually during the first month, the maximum effect is observed after 3 months of continuous administration. If you skip taking the drug, you should not take a double dose the next day. Goldline Plus is recommended to take a course of 6 months, because during this time not only a significant reduction in body weight is achieved, but also correct eating habits are formed. Due to this, the partial effect persists up to 2 years after discontinuation of the drug. The maximum duration of admission should not exceed 1 year, since there are no data from clinical studies on the efficacy and safety of more prolonged use. Reception of Goldline Plus should be stopped if the patient responds poorly to therapy - if for three months of use the reduction in body weight was less than 5%. It should be remembered that Goldline Plus is used only in complex therapy along with low-calorie meals and physical exertion. Go
The side effects of taking Goldline Plus are mainly observed during the first month of taking, they are not serious, do not require pharmacological correction and go away on their own in a month. The following side effects are mainly observed: dry mouth, insomnia, headache, dizziness, anxiety, increased heart rate, increased blood pressure, loss of appetite, constipation, nausea, increased sweating. Go
Installed hypersensitivity to sibutramine or to other components of the drug; The presence of organic causes of obesity (for example, hypothyroidism); Serious eating disorders - anorexia nervosa or bulimia nervosa; Mental illness; Gilles de la Tourette syndrome (generalized tics); Simultaneous intake of MAO inhibitors (for example, phentermine, fenfluramine, dexfenfluramine, ethylamphetamine, ephedrine) or use within 2 weeks before taking Goldline® PLUS and 2 weeks after the end of its administration with other drugs acting on the central nervous system, inhibiting serotonin reuptake (for example, antidepressants, antipsychotics); hypnotic drugs containing tryptophan, as well as other centrally acting drugs for weight loss or for the treatment of mental disorders; Cardiovascular diseases (in the anamnesis or at present): coronary heart disease (myocardial infarction (MI), angina); chronic heart failure in the stage of decompensation, occlusive peripheral arterial disease, tachycardia, arrhythmia, cerebrovascular disease (stroke, transient cerebrovascular accident); Uncontrolled arterial hypertension (arterial pressure (BP) above 145/90 mm Hg) (see also the section "Special Instructions"); Angle-closure glaucoma; Thyrotoxicosis; Severe abnormal liver and / or kidney function; Benign prostatic hyperplasia; Pheochromocytoma; Established pharmacological, drug or alcohol addiction; Pregnancy and breastfeeding period; Age up to 18 years and over 65 years. Precautions should be prescribed the drug in the following conditions: arrhythmias in history, chronic circulatory failure, coronary artery disease (including history), except for coronary heart disease (MI, angina); glaucoma, except for angle-closure glaucoma, cholelithiasis, arterial hypertension (controlled and history), neurological disorders, including mental retardation and convulsions (incl.history), epilepsy, dysfunction of the liver and / or kidneys of mild and moderate severity, motor and verbal tics in history, tendency to bleeding, impaired blood clotting, taking drugs that affect hemostasis or platelet function. Go
Inhibitors of microsomal oxidation, incl. CYP3A4 isoenzyme inhibitors (ketoconazole, erythromycin, cyclosporin, etc.) increase the concentration of sibutramine metabolites in plasma with an increase in heart rate and a clinically insignificant increase in the QT interval. Rifampicin, macrolide antibiotics, phenytoin, carbamazepine, phenobarbital, and dexamethasone can accelerate sibutramine metabolism. The simultaneous use of several drugs that increase the serotonin content in the blood plasma, can lead to the development of a serious interaction. The so-called serotonin syndrome can develop in rare cases with simultaneous use of sibutramine with selective serotonin reuptake inhibitors (drugs for treating depression), with some drugs for treating migraine (sumatriptan, dihydroergotamine), with potent analgesics (pentazine, petidine, fidin. antitussive drugs (dextromethorphan). Sibutramine does not affect the action of oral contraceptives. While taking sibutramine and alcohol, there was no increase in the negative effect of alcohol. However, alcohol is absolutely not combined with the recommended dietary measures when taking sibutramine. The simultaneous use of other drugs with sibutramine that affect hemostasis or platelet function increases the risk of bleeding. Drug interaction with simultaneous use of sibutramine with drugs that increase blood pressure and heart rate, is currently not fully understood. This group of drugs includes decongestants, cough, cough and antiallergic drugs, which include ephedrine or pseudoephedrine. Therefore, in cases of simultaneous administration of these drugs with sibutramine, caution should be exercised. The combined use of sibutramine with drugs for weight loss, acting on the central nervous system, or drugs for the treatment of mental disorders is contraindicated. Go
Goldline® PLUS should be used only in cases where all non-drug weight loss measures are ineffective - if the weight loss for 3 months was less than 5 kg. Treatment with Goldline PLUS should be carried out as part of a comprehensive treatment for weight loss under the supervision of a physician with practical experience in treating obesity. Combined therapy includes both a change in diet and lifestyle, and an increase in physical activity. An important component of therapy is the creation of prerequisites for persistent changes in eating behavior and lifestyle, which are necessary to maintain the achieved weight loss and after the abolition of drug therapy. Patients need to change their lifestyle and habits in the framework of treatment with Goldline PLUS plus in order to ensure that the achieved weight loss is maintained after the completion of treatment. Patients should be clear about the fact that non-compliance with these requirements will lead to a repeated increase in body weight and repeated treatment to the attending physician. In patients taking Goldline PLUS, blood pressure and heart rate should be measured regularly. In the first 3 months of treatment, these parameters should be monitored every 2 weeks, and then monthly.If during two visits in a row an increase in the heart rate at rest> \ 000910 beats per minute or a systolic / diastolic pressure> 10 mm Hg is detected. Art., you must stop treatment. In patients with arterial hypertension, in whom, against the background of antihypertensive therapy, blood pressure is higher than 145/90 mm Hg. Art., this control should be carried out especially carefully and, if necessary, at shorter intervals. In patients whose blood pressure twice during repeated measurements exceeded the level of 145/90 mm Hg. Art., treatment with Goldline PLUS should be canceled (see section “Side Effects”). In patients with sleep apnea, blood pressure should be especially carefully monitored. Special attention requires the simultaneous appointment of drugs that increase the QT interval. These drugs include Hi-histamine blockers (astemizole, terfenadine); antiarrhythmic drugs that increase the QT interval (amiodarone, quinidine, flekainid, meksiletin, propafenone, sotalol); gastrointestinal motility stimulator cisapride; pimozide, sertindol and tricyclic antidepressants. This also applies to conditions that can lead to an increase in the QT interval, such as hypokalemia and hypomagnesemia (see also the section "Interaction with other drugs"). The interval between taking MAO inhibitors (including furazolidone, procarbazine, selegiline) and Goldline® PLUS should be at least 2 weeks. Although there is no link between taking sibutramine and the development of primary pulmonary hypertension, however, given the well-known risk of drugs in this group, regular medical monitoring requires special attention to symptoms such as progressive dyspnea (breathing disorder), chest pain and edema in the legs. . When skipping a dose of Goldline PLUS drug, you should not take a double dose of the drug in the next dose, it is recommended to continue taking the drug as prescribed. The duration of taking the drug Goldline PLUS should not exceed 1 year. When taking sibutramine and other serotonin reuptake inhibitors together, there is an increased risk of bleeding. In patients who are predisposed to bleeding, as well as taking drugs that affect hemostasis or platelet function, sibutramine should be used with caution. Although there are no clinical data on the addiction to sibutramine, it is necessary to find out if there have been any cases of drug dependence in the patient’s history and to pay attention to possible signs of drug abuse. Impact on ability to drive vehicles and mechanisms Taking Goldline® PLUS can limit the ability to drive vehicles and mechanisms. During the period of use of the drug Goldline® PLUS, care should be taken when driving and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions. Go
- Brand name: Abisil
- Active ingredient: Siberian fir terpenes
- Dosage form: Solution for local and external use oil.
- Manufacturer: Canonpharma
- Physical characteristics and chemical degradation of amorphous quinapril hydrochloride
- Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril
- Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat)
- Determination of quinapril and quinaprilat in human plasma by ultraperformance liquid chromatography–electrospray ionization mass spectrometry
- The solid-state stability of amorphous quinapril in the presence of β-cyclodextrins
- Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers
- Solid-state surface acidity and pH-stability profiles of amorphous quinapril hydrochloride and silicate formulations
- Complex effects of drug/silicate ratio, solid-state equivalent pH, and moisture on chemical stability of amorphous quinapril hydrochloride coground with silicates
- Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: In vivo micropuncture studies
- Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection
- Trace analysis of quinapril and its active metabolite, quinaprilat, in human plasma and urine by gas chromatography—negative-ion chemical ionization mass spectrometry
- Determination of dioxopiperazine metabolites of quinapril in biological fluids by gas chromatography—mass spectrometry
- Determination of quinapril and quinaprilat by high-performance liquid chromatography with radiochemical detection, coupled to liquid scintillation counting spectrometry
- Synthesis of carbon-14 labelled quinapril
- Simultaneous determination of hydrochlorothiazide, quinapril and quinaprilat in human plasma by liquid chromatography-tandem mass spectrometry
- Interaction of quinapril anion with cationic surfactant micelles of cetyltrimethylammonium bromide
- Population pharmacokinetics (PK) and pharmacodynamics (PD) of quinapril (Q) in infants, children, and adolescents
- Simultaneous determination of quinapril and its active metabolite quinaprilat in human plasma using high-performance liquid chromatography with ultraviolet detection
- Quinapril and its metabolite quinaprilat in human milk
- Captopril and quinapril reduce reactive oxygen species
- Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension
- Quinapril Treatment Restores The Vasodilator Action Of Insulin In Fructose-Hypertensive Rats
- Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril
- Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria